文献速递乳腺癌放疗

早期乳腺癌全乳切除未放疗后孤立局部区域复发的高危预后因素

Are There High-Risk Prognostic Factors for Isolated Locoregional Recurrence in Patients With Early-Stage Breast Cancer Treated With Mastectomy Without Adjuvant Radiation Therapy?
PubMed 文献 · Adv Radiat Oncol · 2025-08-16

该回顾性研究纳入670例早期乳腺癌接受全乳切除未行术后放疗的患者,中位随访107.1个月,8年局部区域复发率为3.5%。多因素分析证实淋巴血管侵犯(LVI)是复发的独立预测因素,LVI阳性患者8年局部和区域复发率分别为9.5%和9.4%,显著高于LVI阴性者的1%和1.1%。作者建议T1-T2、1-3枚腋窝淋巴结阳性且伴LVI的患者可考虑术后放疗。

要点

  • 早期乳腺癌全乳切除未放疗者8年局部区域复发率为3.5%。
  • LVI阳性者8年局部和区域复发率分别为9.5%和9.4%。
  • LVI是全模型独立的复发预测因素,应纳入放疗决策。

核心结论

  • LVI是早期乳腺癌全乳切除未行术后放疗患者局部区域复发的独立预测因素。
  • T1-T2、1-3枚腋窝淋巴结阳性且伴LVI的早期乳腺癌患者,应考虑术后放疗。

研究设计与样本

  • 共670例符合标准,中位年龄59.4岁(IQR 48-72),中位随访107.1个月(IQR 80.3-138.6)。
  • 采用Kaplan-Meier法估计结局,log-rank检验行单因素分析,Cox比例风险回归估计风险比,P<.05为有统计学意义。

主要发现

  • 队列中T2肿瘤257例(38.3%),pN1 249例(37.1%),组织学3级186例(27.8%),LVI 134例(20%),HER2阳性116例(17.3%),三阴性55例(8.2%)。
  • 2年、5年和8年局部区域复发率分别为1.4%、2.9%和3.5%。
  • 单因素分析显示LVI、G3、肿瘤大小(T)、淋巴结受累(pN1)、雌激素受体阴性、三阴性表型和Ki-67表达与局部区域复发风险升高显著相关。
  • LVI阳性患者8年局部和区域复发率分别为9.5%和9.4%,LVI阴性患者分别为1%和1.1%。
  • 多因素分析证实LVI在所有模型中均为强且独立的复发预测因素。

关键数值与推荐

  • LVI阳性患者8年局部复发率9.5%、区域复发率9.4%,LVI阴性患者分别为1%和1.1%。
  • T1-T2肿瘤、1-3枚腋窝淋巴结阳性且伴LVI的早期乳腺癌患者,应考虑术后放疗。

临床怎么用

  • 对全乳切除后未行术后放疗的早期乳腺癌患者,应评估LVI状态以识别局部区域复发高危者。
  • T1-T2、1-3枚腋窝淋巴结阳性且伴LVI的患者,应与患者讨论并考虑术后放疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aims to investigate whether there are subgroups of patients with early-stage breast cancer (BC) treated with radical mastectomy that are at high risk of locoregional recurrence (LRR) and could benefit from postmastectomy radiation therapy (PMRT). METHODS AND MATERIALS: We retrospectively reviewed patients with early-stage BC treated with mastectomy at our institution between December 2009 and December 2018. Tumors were classified according to molecular subtype and known prognostic factors. Outcomes were estimated using the Kaplan-Meier method. Univariate analysis was performed using the log-rank test, while Cox proportional hazards regression was applied to estimate hazard ratios for evaluating associations between prognostic factors and survival. A P value of <.05 was considered statistically significant. RESULTS: A total of 670 patients who met the selection criteria were identified. Median age was 59.4 years (IQR, 48-72), and the median follow-up was 107.1 months (IQR, 80.3-138.6). Among the cohort, 257 patients (38.3%) had T2 tumors, 249 (37.1%) were pN1, 186 (27.8%) had grade 3 tumors, 134 (20%) presented with lymphovascular invasion (LVI), 116 (17.3%) were HER2-positive, and 55 (8.2%) had triple-negative disease. LRR rates at 2, 5, and 8 years were 1.4%, 2.9%, and 3.5%, respectively. On univariate analysis, the presence of LVI, G3, tumor size (T), nodal involvement (pN1), estrogen receptor-negative status, triple-negative phenotype, and Ki-67 expression were significantly associated with an increased risk of LRR. Notably, LVI-positive patients had significantly higher locoregional and regional recurrence rates at 8 years (9.5% and 9.4%, respectively) compared to LVI-negative patients (1% and 1.1%). Multivariate analysis confirmed LVI as a strong and independent predictor of recurrence across all models. CONCLUSIONS: This study confirms the prognostic relevance of several pathologic factors in predicting LRR, with particular emphasis on the independent role of LVI, in patients with early-stage BC treated with mastectomy and not receiving PMRT. In patients with early-stage BC with T1-T2 tumors and 1-3 positive axillary lymph nodes with the presence of LVI, PMRT should be considered.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Facondo G, Reverberi C, Prisco A, et al. Are There High-Risk Prognostic Factors for Isolated Locoregional Recurrence in Patients With Early-Stage Breast Cancer Treated With Mastectomy Without Adjuvant Radiation Therapy? Adv Radiat Oncol. 2025. PMID: 41142181. doi:10.1016/j.adro.2025.101877

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。